MK0991, caspofungin acetate + Comparator: amphotericin B + Comparator: lipid formulation of amphotericin B and/or azole

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Aspergillosis

Conditions

Aspergillosis

Trial Timeline

Jan 1, 2003 → Aug 1, 2005

NCT ID

NCT00076869

About MK0991, caspofungin acetate + Comparator: amphotericin B + Comparator: lipid formulation of amphotericin B and/or azole

MK0991, caspofungin acetate + Comparator: amphotericin B + Comparator: lipid formulation of amphotericin B and/or azole is a phase 2 stage product being developed by Merck for Aspergillosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00076869. Target conditions include Aspergillosis.

What happened to similar drugs?

8 of 16 similar drugs in Aspergillosis were approved

Approved (8) Terminated (6) Active (6)

✅MicafunginAstellas PharmaApproved

✅micafungin + voriconazoleAstellas PharmaApproved

✅MicafunginAstellas PharmaApproved

✅caspofunginMerckApproved

✅SOC +Posaconazole 18 MG/ML (milligram/milliliter)MerckApproved

✅Ambisome + caspofunginGilead SciencesApproved

✅anidulafungin and voriconazolePfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00076869	Phase 2	Completed	Jan 1, 2003	Aug 1, 2005	Aspergillosis

Competing Products

20 competing products in Aspergillosis

See all competitors

Product	Company	Stage	Hype Score
Micafungin + Liposomal Amphotericin B	Astellas Pharma	Phase 2	27
Micafungin	Astellas Pharma	Approved	35
isavuconazole	Astellas Pharma	Phase 3	40
Micafungin + Systemic antifungal therapy	Astellas Pharma	Phase 2	27
Isavuconazole + Voriconazole	Astellas Pharma	Phase 3	40
micafungin + voriconazole	Astellas Pharma	Approved	35
FK463	Astellas Pharma	Phase 2	35
Micafungin	Astellas Pharma	Approved	35
Olorofim + AmBisome®	Shionogi	Phase 3	44
Prednisolone + Voriconazole	Cipla	Phase 2/3	38
Posaconazole + Voriconazole	Merck	Phase 3	40
caspofungin	Merck	Approved	39
SOC +Posaconazole 18 MG/ML (milligram/milliliter)	Merck	Approved	43
caspofungin acetate	Merck	Phase 2	35
Posaconazole IV + Posaconazole PFS + Posaconazole tablet	Merck	Phase 2	35
AmBisome	Gilead Sciences	Phase 3	40
Ambisome + caspofungin	Gilead Sciences	Approved	43
nebulised liposomal amphotericin B	Gilead Sciences	Phase 2/3	38
Voriconazole + Voriconazole	Pfizer	Phase 2	35
Isavuconazole	Pfizer	Pre-clinical	26